AP NEWS
Press release content from BusinessWire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from BusinessWire
Press release content from BusinessWire. The AP news staff was not involved in its creation.

Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline Insights, 2019 Report - ResearchAndMarkets.com

January 31, 2019

DUBLIN--(BUSINESS WIRE)--Jan 31, 2019--The “Chemotherapy Induced Peripheral Neuropathy (CIPN) - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Chemotherapy Induced Peripheral Neuropathy (CIPN) - Pipeline Insight, 2019 report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Chemotherapy Induced Peripheral Neuropathy (CIPN) development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Chemotherapy Induced Peripheral Neuropathy (CIPN) pipeline products by developmental stage, product type, molecule type, and administration route.

Key Topics Covered:

1. Report Introduction

2. Chemotherapy Induced Peripheral Neuropathy (CIPN) Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Chemotherapy Induced Peripheral Neuropathy (CIPN)

4. Comparative Analysis

5. Products in Clinical Stage

Product Description Research and Development Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment

Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type

8. Inactive Products

Product Description Research and Development Product Development Activities

Companies Mentioned (Partial List)

Achelios Therapeutics Inc Advinus Therapeutics Ltd Apollo Endosurgery Inc Aptinyx Inc Asahi Kasei Pharma Corp Can-Fite BioPharma Ltd Celgene Corp DermaXon LLC Eisai Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/pdtt5b/chemotherapy?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190131005773/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/31/2019 12:57 PM/DISC: 01/31/2019 12:57 PM

http://www.businesswire.com/news/home/20190131005773/en